A new AI model accurately detected cardiac amyloidosis from echocardiograms with higher accuracy vs. other amyloidosis risk ...

In a new study published in the European Heart Journal, researchers reported the successful development and validation of a ...

A large-scale, multi-center international study published in the European Heart Journal has shown that EchoGo® Amyloidosis, ...

An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in ...

It is hoped that identifying those most at risk of Transthyretin Amyloidosis Cardiomyopathy will lead to an earlier diagnosis ...

ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and ...

The AI model uses a single echocardiography videoclip to differentiate cardiac amyloidosis from other similar heart ...

Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% ...

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Amyloidosis therapeutics market was valued at US$ 2.95 billion in 2024 and is projected to hit the market valuation of US$ 6.37 billion by 2033 at a CAGR of 9.20% during the forecast period 2025–2033.

In a new study published in the European Heart Journal , researchers reported the successful development and validation of a medical artificial ...